CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...